Uniqure N V's Customers Performance

Name: Uniqure N V Customers by Division and Industry - CSIMarket
Creator: CSIMarket.com
License: https://csimarket.com/help/terms-of-use

QURE

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.


QURE's Source of Revenues		During the corresponding time, Uniqure N V recorded a revenue increase by 127.31 % year on year, sequentially revenue fell by -36.03 %. While revenue at the Uniqure N V 's corporate clients • List of QURE Customers

for the same period Uniqure N V recorded revenue increase by 127.31 % year on year, sequentially revenue fell by -36.03 %.

• List of QURE Customers

Uniqure N V's Business Units


Single Reportable Segment		263.98 %	of total Revenue

Select the Relationship:

Customers ▼

Select the Category:

Comparison ▼

Customers ▼

Basic Report▼

Uniqure N V's Comment on Sales, Marketing and Customers

News about Uniqure N v Contracts

uniQures AMT-130 Gene Therapy Shows Promise in Slowing Disease Progression in Huntingtons Disease Trials

Huntington s disease is a rare, inherited neurodegenerative disorder that causes the progressive deterioration of nerve cells in the brain, leading to motor, cognitive, and psychiatric symptoms. Unfortunately, there is currently no cure for this debilitating condition, making uniQure s AMT-130 gene therapy a potential game-changer in the field of Huntington s disease treatment.The interim results of the Phase I/II trials have shown highly positive outcomes, indicating the efficacy and durability of AMT-130 in slowing down the progression of Huntington s disease. The statistically significant, dose-dependent responses observed are highly encouraging, offering renewed hope for patients and fueling optimism amo...

uniQures Strategic Divestiture Streamlining Operations for Future Growth

In a significant move aimed at streamlining its operations and reducing operating expenses, leading gene therapy company uniQure has recently announced the sale of its commercial manufacturing facility to Genezen. This strategic divestiture marks a vital milestone for uniQure, as it seeks to focus on its core competencies and pave the way for future growth. The decision holds promising implications for both companies and the wider gene therapy industry as it reinforces uniQure s commitment to innovation and cost optimization.Streamlining Operations for Enhanced Focus:The sale of its commercial manufacturing facility represents a proactive step by uniQure to refine its business strategies and align resources ...

Progress Unveiled: uniQure's Groundbreaking AMT-130 Gene Therapy and its Potential in Treating Huntington's Disease

Amid the relentless pursuit of finding a cure for neurological disorders, uniQure a leading gene therapy company reveals a significant development that may blaze trails in treating Huntington’s disease. The update revolves around the Phase I/II clinical trials of their pioneering therapy, AMT-130, which could potentially transform the medical landscape for Huntington s disease patients globally.
uniQure specializes in developing genetic therapies with the potential to improve the lives of patients afflicted with serious genetic disorders. AMT-130 an AAV-based gene therapy is one of their latest developments offering promising outlooks. This innovation aims to reduce or prevent the effects of the H...

QURE's Stock Performance relative to it's Customers

QURE's vs. Customers, Data

(Revenue and Income for Trailing 12 Months, in Millions of $, except Employees)

COMPANY NAME	MARKET CAP	REVENUES	INCOME	EMPLOYEES
Uniqure N v	2,665.94	18.09	-208.87	221
SUBTOTAL	0.00	0.00	0.00	-

Sources: Uniqure N v’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: Uniqure N v’s corporate clients.
For your research, we’ve provided 9 tables on Uniqure N v corporate clients.
You can find them in the navigation menu under Customers & Markets.
To download the tables, please subscribe.

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.